Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-oral-btk-inhibitor-chronic-spontaneous-2025a1000q9c?src=rss
Author :
Publish date : 2025-10-01 07:09:00
Copyright for syndicated content belongs to the linked Source.
